

AUSTRALIAN PRODUCT INFORMATION WYOST® (DENOSUMAB) SOLUTION FOR INJECTION

1. NAME OF THE MEDICINE

Denosumab

WYOST (denosumab) is a biosimilar medicine to Xgeva®.

The evidence for comparability supports the use of WYOST for the listed indications.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains a deliverable dose of 120 mg denosumab in 1.7 mL of solution (70 mg/mL).

Denosumab is a human IgG2 monoclonal antibody with high affinity and specificity for RANK ligand (RANKL). Denosumab has an approximate molecular weight of 145 kDa and is produced in genetically engineered mammalian (Chinese Hamster Ovary, CHO) cells.

For the full list of excipients, see section 6.1 List of excipients.

3. PHARMACEUTICAL FORM

WYOST is supplied as a sterile, preservative-free, clear, colourless to slightly yellowish or slightly brownish solution for injection at pH approx. 5.2.

4. CLINICAL PARTICULARS

4.1. THERAPEUTIC INDICATIONS

Prevention of skeletal related events in patients with multiple myeloma and in patients with bone metastases from solid tumours.

Treatment of giant cell tumour of bone in adults or skeletally mature adolescents that is recurrent, or unresectable, or resectable but associated with severe morbidity.

Treatment of hypercalcaemia of malignancy that is refractory to intravenous bisphosphonate.

4.2. DOSE AND METHOD OF ADMINISTRATION

Dosage (dose and interval)

The recommended dose of WYOST for the prevention of skeletal related events is 120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm.

The recommended dose of WYOST for the treatment of giant cell tumour of bone and hypercalcaemia of malignancy is 120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm with a loading dose of 120 mg on days 8 and 15 of the initial 4-week treatment period.

Daily supplementation with at least 500 mg calcium and 400 IU vitamin D is required in all patients, unless hypercalcaemia is present (see Section 4.4 Special warnings and precautions for use, Vitamin supplementation and hypocalcaemia).

Method of administration

Administration should be performed by an individual who has been adequately trained in injection techniques.

Before administration, the WYOST solution for injection should be inspected for particulate matter and discolouration. Do not use if the solution is cloudy or contains visible particles.. Do not shake. To avoid discomfort at the site of injection, allow the vial to reach room temperature (up to 25°C) before injecting, and inject slowly. A 27-gauge needle or larger needle (e.g. 25-gauge) is recommended for the administration of WYOST.

Product is for single-use in one patient only.

Inject the entire contents of the vial. Do not re-insert the needle into the vial.

Dispose of any medicinal product remaining in the vial.

Dosage adjustment

Special populations

Use in elderly

No dose adjustment is necessary in elderly patients (see section 4.4 Special warnings and precautions for use, Use in the elderly)

Renal impairment

No dose adjustment is necessary in patients with renal impairment (see section 4.4 Special warnings and precautions for use, Use in renal impairment).

Use in paediatrics

For treatment of giant cell tumour of bone in skeletally mature adolescents, the posology is the same as in adults.

WYOST is not recommended in paediatric patients (age < 18) other than skeletally mature paediatric patients with giant cell tumour of bone (see Section 4.4 Special warnings and precautions for use, Paediatric use).

4.3. CONTRAINDICATIONS

Pregnancy (see section 4.6 Fertility, pregnancy and lactation, Use in pregnancy).

Hypersensitivity to the active substance, to CHO-derived proteins or to any of the excipients (see section 6.1 List of excipients).

Severe untreated hypocalcaemia.

Unhealed lesions from dental or oral surgery.

4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Vitamin supplementation and hypocalcaemia

Pre-existing hypocalcaemia must be corrected prior to initiating therapy with denosumab. Supplementation with calcium and vitamin D is required in all patients unless hypercalcaemia is present.

Hypocalcaemia can occur at any time during therapy with denosumab. Monitoring of calcium levels should be conducted (i) prior to the initial dose of denosumab, (ii) within two weeks after the initial dose, (iii) if suspected symptoms of hypocalcaemia occur (see Section 4.8 Adverse effects (Undesirable effects) for symptoms). Additional monitoring of calcium level should be considered during therapy in patients with risk factors for hypocalcaemia, or if otherwise indicated based on the clinical condition of the patient. Patients should be encouraged to report symptoms indicative of hypocalcaemia.

In the post-marketing setting, severe symptomatic hypocalcaemia (including fatal cases) has been reported (see Section 4.8 Adverse effects (Undesirable effects), Post-marketing experience), with most cases occurring in the first weeks of initiating therapy, but can occur later.

If hypocalcaemia occurs while receiving denosumab, additional short term calcium supplementation may be necessary (see Section 4.4 Special warnings and precautions for use, Use in renal impairment and Section 4.8 Adverse effects (Undesirable effects), Post-marketing experience).

Osteonecrosis of the jaw

Osteonecrosis of the jaw (ONJ) has occurred in patients treated with denosumab, with the majority of cases occurring within 5 months after the last dose. In clinical trials, the incidence of ONJ was higher with longer duration of exposure (see Section 4.8 Adverse effects (Undesirable effects)).

Patients who developed ONJ in clinical studies generally had known risk factors for ONJ, including invasive dental procedures (e.g., tooth extraction, dental implants, oral surgery), poor oral hygiene or other pre-existing dental disease, local gum or oral infection, advanced malignancies, or concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors). An oral examination should be performed by the prescriber prior to initiation of WYOST treatment and a dental examination with appropriate preventive dentistry is recommended prior to treatment with WYOST, especially in patients with risk factors for ONJ. Good oral hygiene practices should be maintained during treatment with denosumab.

Patients should avoid invasive dental procedures during treatment with WYOST. For patients in whom invasive dental procedures cannot be avoided, the clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit-risk assessment. Patients who are suspected of having or who develop ONJ while on WYOST should receive care by a dentist or an oral surgeon. If ONJ occurs during treatment with WYOST a temporary interruption of treatment should be considered based on individual benefit-risk assessment until the condition resolves.

Atypical femoral fractures

Atypical femoral fracture has been reported with denosumab (see Section 4.8 Adverse effects (Undesirable effects)). Atypical femoral fractures may occur with little or no trauma in the

subtrochanteric and diaphyseal regions of the femur and may be bilateral. Specific radiographic findings characterise these events. Atypical femoral fractures have also been reported in patients with certain co-morbid conditions (e.g. vitamin D deficiency, rheumatoid arthritis, hypophosphatasia) and with use of certain pharmaceutical agents (e.g. bisphosphonates, glucocorticoids, proton pump inhibitors).

These events have also occurred without antiresorptive therapy. During treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Patients presenting with such symptoms should be evaluated for an incomplete femoral fracture, and the contralateral femur should also be examined.

Hypercalcaemia following treatment discontinuation in patients with giant cell tumour of bone and in patients with growing skeletons

Clinically significant hypercalcaemia requiring hospitalisation and complicated by acute renal injury has been reported in denosumab-treated patients with giant cell tumour of bone and patients with growing skeletons weeks to months following treatment discontinuation. After treatment is discontinued, monitor patients for signs and symptoms of hypercalcaemia, consider periodic assessment of serum calcium as clinically indicated, and treat appropriately. Re-evaluate the patient's calcium and vitamin D supplementation requirements. Manage hypercalcaemia as clinically appropriate (see Section 4.4 Special warnings and precautions for use, Paediatric use and Section 4.8 Adverse effects (Undesirable effects)).

Multiple vertebral fractures (MVF) following treatment discontinuation

Multiple vertebral fractures (MVF), not due to bone metastases, may occur following discontinuation of treatment with WYOST, particularly in patients with risk factors such as osteoporosis or prior fractures.

Advise patients not to interrupt treatment without their physician's advice. When WYOST treatment is discontinued, evaluate the individual patient's risk for vertebral fractures (see Section 4.8 Adverse effects (Undesirable effects)).

Drugs with same active ingredient

Patients being treated with WYOST should not be treated concomitantly with other denosumab-containing medicinal products (used for the treatment of postmenopausal osteoporosis).

Warnings for excipients

Patients with rare hereditary problems of fructose intolerance should not use WYOST.

Use in hepatic impairment

The safety and efficacy of denosumab has not been studied in patients with hepatic impairment.

Use in renal impairment

No dose adjustment is necessary in patients with renal impairment.

In clinical studies of subjects without advanced cancer, but with varying degrees of renal

function (including patients with severe renal impairment [creatinine clearance < 30 mL/min] or receiving dialysis) there was a greater risk of developing hypocalcaemia with increasing degree of renal impairment, and in the absence of calcium supplementation. Monitoring calcium levels and adequate intake of calcium and vitamin D is important in patients with severe renal impairment or receiving dialysis (see Section 4.4 Special warnings and precautions for use, Vitamin supplementation and hypocalcaemia).

Use in the elderly

Of the total number of patients in clinical studies in patients with advanced cancer, 1260 patients (44.4%) treated with denosumab were ≥ 65 years old. No overall differences in safety or efficacy were observed between these patients and younger patients.

Paediatric use

The safety and efficacy of denosumab in paediatric patients (age < 18) have not been established other than skeletally mature adolescents with giant cell tumour of bone. WYOST is not recommended for use in paediatric patients other than skeletally mature adolescents with giant cell tumour of bone. Clinically significant hypercalcaemia after treatment discontinuation has been reported in the post-marketing setting in paediatric patients with growing skeletons who received denosumab for giant cell tumour of bone or for unapproved indications (see Section 4.4 Special warnings and precautions for use, Hypercalcaemia following treatment discontinuation in patients with giant cell tumour of bone and in patients with growing skeletons).

In Study 20062004, denosumab has been evaluated in a subset of 28 adolescent patients (aged 13-17 years) with giant cell tumour of bone who had reached skeletal maturity defined by at least 1 mature long bone (e.g., closed epiphyseal growth plate of the humerus) and body weight ≥ 45 kg. Efficacy results in skeletally mature adolescents appeared to be similar to those observed in adults (see Section 5.1 Pharmacodynamic properties, Clinical trials).

Adolescent primates had abnormal growth plates when administered denosumab at doses of 10 mg/kg and higher, which resulted in exposures up to 2.8 times those observed in adult humans dosed at 120 mg subcutaneously every 4 weeks based on AUC. In neonatal cynomolgus monkeys exposed in utero to denosumab at 50 mg/kg, there was increased postnatal mortality; abnormal bone growth resulting in reduced bone strength, reduced haematopoiesis, and tooth malalignment; absence of peripheral lymph nodes; decreased neonatal growth and other adverse effects (see Section 4.6 Fertility, pregnancy and lactation, Use in Pregnancy). In neonatal rats, inhibition of RANKL (target of denosumab therapy) with a construct of osteoprotegerin bound to Fc (OPG-Fc) was associated with inhibition of bone growth and tooth eruption and lower body weight gain. These changes were partially reversible when dosing of RANKL inhibitor was discontinued. Therefore, treatment with denosumab may impair bone growth in children with open growth plates and may inhibit eruption of dentition.

Effects on laboratory tests

No interactions with laboratory and diagnostic tests have been identified.

4.5. INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

No drug-drug interaction studies have been conducted.

In clinical studies, denosumab has been administered in combination with standard anticancer treatment and in patients previously receiving bisphosphonates.

The pharmacokinetics and pharmacodynamics of denosumab were not altered by concomitant chemotherapy and/or hormone therapy nor by previous IV bisphosphonate exposure.

Denosumab should not be administered concomitantly with bisphosphonates.

4.6. FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

No data are available on the effect of denosumab on human fertility. Denosumab had no effect on female fertility or male reproductive organs or sperm motility in cynomolgus monkeys at subcutaneous doses up to 12.5 mg/kg/week (females) or 50 mg/kg/month (males), yielding exposures that were approximately 15-fold higher than the human exposure at 120mg subcutaneous administered once every month.

Use in pregnancy

Pregnancy Category: D

There are no adequate and well-controlled studies of denosumab in pregnant women. WYOST is contraindicated for use during pregnancy. Advise females of reproductive potential to use highly effective contraception during therapy, and for at least 5 months after the last dose of WYOST. Any effects of denosumab are likely to be greater during the second and third trimesters of pregnancy since monoclonal antibodies are transported across the placenta in a linear fashion as pregnancy progresses, with the largest amount transferred during the third trimester. Inform the patient of the potential hazard to a foetus if the patient becomes pregnant while exposed to denosumab.

Developmental toxicity studies have been performed with denosumab in cynomolgus monkeys and have shown serious adverse effects on development (including foetal and infant lethality). Denosumab was shown to cross the placenta in monkeys.

In a study of cynomolgus monkeys with denosumab at 12.5 mg/kg/week given during the period equivalent to the first trimester at AUC exposures up to 10-fold higher than the human dose (120 mg every 4 weeks), there was no evidence of maternal or foetal harm. In this study, foetal lymph nodes were not examined.

In another study of cynomolgus monkeys with denosumab throughout pregnancy at 50 mg/kg/month, yielding AUC exposures 12-fold higher than the human dose (120 mg every 4 weeks), there were increased stillbirths and postnatal mortality; abnormal bone growth resulting in reduced bone strength, almost complete obliteration of bone marrow spaces (leading to reduced haematopoiesis), and tooth malalignment, dental dysplasia and shortened/straighter dental arch (although no effect on the pattern or date of tooth eruption); altered appearance of eyes (increased apparent size, exophthalmos); absence of peripheral lymph nodes; and decreased neonatal growth. Following a 6 month period after birth, bone-related changes showed incomplete recovery. The effects on lymph nodes, tooth malalignment and dental dysplasia persisted, and minimal to moderate mineralisation in multiple tissues was seen in one animal. There was no evidence of maternal harm prior to labour; adverse maternal

effects occurred infrequently during labour. Maternal mammary gland development was normal. A no observed adverse effect level has not been established in animal studies and the findings are attributable to the primary pharmacological activity of denosumab.

Preclinical studies in RANK/RANKL-knockout mice suggest absence of RANKL could interfere with the development of lymph nodes in the foetus. Knockout mice lacking RANK or RANKL also exhibited decreased body weight, reduced bone growth and a lack of tooth eruption. Similar phenotypic changes (inhibition of bone growth and tooth eruption) were observed in a study in neonatal rats using a surrogate for denosumab, the RANKL inhibitor osteoprotegerin bound to Fc (OPG-Fc). These changes were partially reversible when dosing of RANKL inhibitor was discontinued. Therefore, treatment with denosumab may impair bone growth in children with open growth plates and may inhibit eruption of dentition.

Preclinical studies in RANK/RANKL-knockout mice suggest absence of RANKL during pregnancy may interfere with maturation of the mammary gland leading to impaired lactation post-partum.

Use in lactation

It is unknown whether denosumab is excreted in human milk. Only limited excretion of denosumab in milk was observed in a study in monkeys. A decision on whether to abstain from breast-feeding or to abstain from therapy with WYOST should be made, taking into account the benefit of breast-feeding to the newborn/infant and the benefit of therapy.

4.7. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

No studies on the effects on the ability to drive or use machinery have been performed.

4.8. ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Bone metastasis from solid tumours

Data from three active-controlled multicentre trials were used for the safety analysis in 5677 patients with bone metastases from either prostate cancer, breast cancer, other solid tumours or patients with multiple myeloma (all patients with advanced cancer). A total of 2841 patients were exposed to 120 mg of denosumab administered once every 4 weeks as a single subcutaneous injection, and 2836 patients were exposed to 4 mg (dose-adjusted for reduced renal function) of zoledronic acid administered once every 4 weeks as an IV infusion. The median (Q1, Q3) duration of exposure to denosumab for the safety analysis was 12 months (6, 18) for prostate cancer, 17 months (10, 21) for breast cancer, and 7 months (4, 14) for other solid tumours and multiple myeloma.

Table 1. Percentage of Patients with Adverse Events in Patients with Advanced Malignancies Involving Bone by Body System ($\geq 10\%$ Incidence in Either Treatment Group)

System Organ Class Preferred Term	Denosumab (N = 2841) n (%)	Zoledronic Acid (N = 2836) n (%)
Blood and lymphatic system disorders		
Anaemia	771 (27.1)	859 (30.3)
Gastrointestinal disorders		
Nausea	876 (30.8)	895 (31.6)
Constipation	603 (21.2)	670 (23.6)
Diarrhoea	577 (20.3)	530 (18.7)
Vomiting	566 (19.9)	570 (20.1)
Abdominal pain	292 (10.3)	280 (9.9)

System Organ Class Preferred Term	Denosumab (N = 2841) n (%)	Zoledronic Acid (N = 2836) n (%)
General disorders and administration site conditions		
Fatigue	769 (27.1)	766 (27.0)
Asthenia	607 (21.4)	621 (21.9)
Oedema peripheral	472 (16.6)	462 (16.3)
Pyrexia	409 (14.4)	562 (19.8)
Investigations		
Weight decreased	330 (11.6)	332 (11.7)
Metabolism and nutrition disorders		
Decreased appetite	656 (23.1)	694 (24.5)
Musculoskeletal and connective tissue disorders		
Back pain	718 (25.3)	747 (26.3)
Arthralgia	570 (20.1)	632 (22.3)
Bone pain	564 (19.9)	639 (22.5)
Pain in extremity	524 (18.4)	550 (19.4)
Musculoskeletal pain	357 (12.6)	385 (13.6)
Nervous system disorders		
Headache	360 (12.7)	382 (13.5)
Psychiatric disorders		
Insomnia	302 (10.6)	324 (11.4)
Respiratory, thoracic, and mediastinal disorders		
Dyspnoea	585 (20.6)	507 (17.9)
Cough	437 (15.4)	419 (14.8)

N = number of patients who received ≥ 1 active dose of investigational product
 n = number of patients reporting ≥ 1 event

Hypophosphataemia has been reported as a common adverse drug reaction.

Giant cell tumour of bone

The safety of denosumab was evaluated in two phase 2 open-label, single arm studies in which a total of 548 patients with giant cell tumour of bone received at least 1 dose of denosumab.

Patients received 120 mg denosumab subcutaneously every 4 weeks with a loading dose of 120 mg on days 8 and 15 of the initial 4-week period. Of the 548 patients who received denosumab, 467 patients were treated with denosumab for ≥ 1 year, 323 patients for ≥ 2 years, 255 patients for ≥ 3 years, 195 patients for ≥ 4 years and 149 patients for ≥ 5 years. The median (Q1, Q3) number of doses received was 33.0 (17.0, 63.0); the minimum number of doses received was 4 and the maximum was 138. The median (Q1, Q3) number of months on study was 59.61 (28.52, 79.61). The median (range) age was 33 (13 to 83) years; 28 subjects were skeletally

mature adolescents (aged 13 to 17 years).

The overall safety and tolerability profile of denosumab in patients with giant cell tumour of bone was similar to that reported in trials of patients with bone metastases from solid tumours. For skeletally mature adolescent subjects with GCTB, the safety profile appears to be similar to that in adult subjects with GCTB.

The most common adverse reactions in patients with giant cell tumour of bone receiving denosumab (per-patient incidence greater than or equal to 20%) were arthralgia, back pain, pain in extremity, fatigue, headache and, nausea.

Hypercalcaemia following treatment discontinuation in patients with giant cell tumour of bone has been observed uncommonly.

Hypercalcaemia of malignancy

The safety of denosumab was evaluated in an open-label, single-arm trial (Study 20070315) in which 33 patients were enrolled with hypercalcaemia of malignancy (with or without bone metastases) refractory to treatment with intravenous bisphosphonate. Patients received denosumab subcutaneously every 4 weeks with additional 120 mg doses on Days 8 and 15 of the initial 4-week period. Entry criteria included patients who had refractory hypercalcaemia of malignancy (defined as an albumin-corrected calcium of > 12.5 mg/dL [3.1 mmol/L] despite treatment with intravenous bisphosphonate in the last 7-30 days). Patients receiving dialysis for renal failure or who had treatment with thiazides, calcitonin, mithromycin, or gallium nitrate within their window of expected therapeutic effect prior to the date of screening corrected serum calcium (CSC) were excluded. During the trial, serum calcium was collected every few days in the first month, weekly during the second month, and monthly thereafter.

Of the 33 patients who received denosumab, 33 patients were treated with denosumab for ≥ 1 month, 5 patients for ≥ 6 months, and 3 patients for ≥ 1 year. The median number of doses received was 4 (range: 1 to 25 doses) and the median number of months on study was 1.8 (range: 0 to 23 months). Sixty-four percent of enrolled patients were men and 70% were white. The median age was 63 years (range: 22 to 89 years).

The adverse reaction profile of denosumab in patients with hypercalcaemia of malignancy was similar to that reported in patients with bone metastases from solid tumours and giant cell tumour of bone.

The most common adverse reactions were nausea, dyspnoea, decreased appetite, headache, peripheral oedema, and vomiting. No adverse events leading to discontinuation were reported as related to denosumab.

Hypocalcaemia

In three phase 3 active-controlled clinical trials in patients with advanced malignancies involving bone, hypocalcaemia was reported in 9.6% of patients treated with denosumab and 5.0% of patients treated with zoledronic acid. A decrease in serum calcium levels to the range between 1.5 to 1.75 mmol/L was experienced in 2.5% of patients treated with denosumab and 1.2% of patients treated with zoledronic acid. A decrease in serum calcium levels to < 1.5 mmol/L was experienced in 0.6% of patients treated with denosumab and 0.2% of patients treated with zoledronic acid.

In a phase 3 active-controlled clinical trial in patients with newly diagnosed multiple myeloma,

hypocalcaemia was reported in 16.9% of patients treated with denosumab and 12.4% of patients treated with zoledronic acid. A decrease in serum calcium levels to the range between 1.5 to 1.75 mmol/L was experienced in 1.4% of patients treated with denosumab and 0.6% of patients treated with zoledronic acid. A decrease in serum calcium levels to the range between 0.8 to 1.5 mmol/L was experienced in 0.4% of patients treated with denosumab and 0.1% of patients treated with zoledronic acid.

In two phase 2 open-label trials in patients with giant cell tumour of bone, hypocalcaemia was reported in 5.7% of patients. None of the adverse events was considered serious.

In a phase 2 open-label, single-arm trial in patients with hypercalcaemia of malignancy refractory to intravenous bisphosphonate, hypocalcaemia was reported in 9.1% of patients treated with denosumab.

Osteonecrosis of the jaw (ONJ)

In the primary treatment phase of three phase 3 active-controlled clinical trials in patients with advanced malignancies involving bone, ONJ was confirmed in 1.8% of patients treated with denosumab (median exposure of 12 months; range 0.1 to 40.5) and 1.3% of patients treated with zoledronic acid. Clinical characteristics of these cases were similar between treatment groups.

Among subjects with confirmed ONJ, most had a history of tooth extraction, poor oral hygiene, and/or use of a dental appliance. In addition, most subjects were receiving or had received chemotherapy. The trials in patients with breast or prostate cancer included a pre-specified extension treatment phase (median overall exposure of 14.9 months; range 0.1 – 67.2) where patients were offered open label denosumab. The patient-year adjusted incidence of confirmed ONJ was 1.1 per 100 patient-years during the first year of treatment, 3.7 in the second year and 4.6 thereafter. The median time to ONJ was 20.6 months (range: 4 - 53).

In a phase 3 double-blind, active-controlled clinical trial in patients with newly diagnosed multiple myeloma, ONJ was confirmed in 4.1% of patients in the denosumab group (median exposure of 15.8 months; range 1 – 49.8) and 2.8% of patients in the zoledronic acid group. At the completion of the double-blind treatment phase of this trial, the patient-year adjusted incidence of confirmed ONJ in the denosumab group (median exposure of 19.4 months; range 1 – 52) was 2.0 per 100 patient-years during the first year of treatment, 5.0 in the second year, and 4.5 thereafter. The median time to ONJ was 18.7 months (range: 1 – 44).

In a phase 3 placebo-controlled clinical trial with an extension treatment phase evaluating denosumab for the prevention of bone metastases in patients with non-metastatic prostate cancer (a patient population for which denosumab is not indicated), with longer treatment exposure of up to 7 years, the patient-year adjusted incidence of confirmed ONJ was 1.1 per 100 patient-years during the first year of treatment, 3.0 in the second year, and 7.1 thereafter.

In two phase 2 open-label studies in patients with giant cell tumour of bone, ONJ occurred in 4 of 304 (1.3%) of patients. The median time to ONJ was 16 months (range 13-20).

In a phase 2 open-label, single-arm trial in patients with hypercalcaemia of malignancy refractory to intravenous bisphosphonate, no cases of ONJ were reported.

In a phase 2 open-label clinical trial in patients with giant cell tumor of bone, ONJ was confirmed in 6.8% of patients (median number of 34 doses; range 4 – 116). At the completion

of the trial, median time on trial including safety follow-up phase was 60.9 months (range: 0 – 112.6). The patient-year adjusted incidence of confirmed ONJ was 1.5 per 100 patient-years overall (0.2 per 100 patient-years during the first year of treatment, 1.5 in the second year, 1.8 in the third year, 2.1 in the fourth year, 1.4 in the fifth year, and 2.2 thereafter). The median time to ONJ was 41 months (range: 11 - 96).

Atypical femoral fractures

Atypical femoral fracture has been reported uncommonly in patients treated with denosumab and the risk increased with longer duration of treatment. Events have occurred during treatment and up to 9 months after treatment was discontinued.

Paediatric patients

The safety profile of denosumab in 28 skeletally mature adolescent patients with giant cell tumour of bone was consistent with that in adult patients.

Drug hypersensitivity events

In clinical trials in patients with advanced cancer, drug hypersensitivity events were reported in 0.9% and 0.4% of patients treated with denosumab and zoledronic acid, respectively.

Pancreatitis

In a randomised controlled trial in postmenopausal women with osteoporosis receiving 60 mg denosumab or placebo once every 6 months, pancreatitis was reported in 8 patients (0.2%) in the denosumab and 4 patients (0.1%) in the placebo groups. An increased incidence has not been observed in randomised controlled trials in the oncology setting.

Hypercalcaemia

Hypercalcaemia has been observed following treatment discontinuation in patients with growing skeletons (a patient population for which WYOST is not indicated).

Multiple vertebral fractures

Multiple vertebral fractures, not due to bone metastases, have occurred in patients with risk factors such as osteoporosis or prior fractures following treatment discontinuation.

Post-marketing experience

The following adverse reactions have been identified during post approval use of denosumab:

Rare events of severe symptomatic hypocalcaemia (including fatal cases) have been reported in patients at increased risk of hypocalcaemia. Examples of the clinical manifestations of severe symptomatic hypocalcaemia have included QT interval prolongation, tetany, seizures and altered mental status (see Section 4.4 Special warnings and precautions for use, Vitamin supplementation and hypocalcaemia). Symptoms of hypocalcaemia in denosumab clinical studies included paraesthesias or muscle stiffness, twitching, spasms and muscle cramps.

Hypersensitivity, including anaphylactic reactions. Musculoskeletal pain, including severe cases.

Lichenoid drug eruptions (e.g., lichen planus-like reactions) have been observed uncommonly.

Alopecia has been observed commonly.

There have been reports of osteonecrosis of the external auditory canal in patients using denosumab.

Comparability of WYOST with reference medicine (Xgeva)

The types, frequency and severity of adverse events were comparable between WYOST and the reference medicine.

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9. OVERDOSE

There is no experience with overdosage with denosumab. Denosumab has been administered in clinical studies using doses up to 180 mg every 4 weeks (cumulative doses up to 1080 mg over 6 months), and 120 mg weekly for 3 weeks.

For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5. PHARMACOLOGICAL PROPERTIES

5.1. PHARMACODYNAMIC PROPERTIES

Mechanism of action

Bone metastasis from solid tumours

RANKL exists as a transmembrane or soluble protein. RANKL is essential for the formation, function and survival of osteoclasts, the sole cell type responsible for bone resorption. Increased osteoclast activity, stimulated by RANKL, is a key mediator of bone destruction in bone disease in metastatic tumours and multiple myeloma. Denosumab binds with high affinity and specificity to RANKL, preventing RANKL from activating its only receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of RANKL-RANK interaction results in reduced osteoclast numbers and function, and thereby decreases bone resorption and cancer-induced bone destruction.

RANKL inhibition resulted in reduced bone lesions and delayed formation of de novo bone metastases in some nonclinical models. RANKL inhibition reduced skeletal tumour growth and this effect was additive when combined with other anticancer therapies.

Giant cell tumour of bone

Giant cell tumours of bone are characterised by stromal cells expressing RANKL and osteoclast-like giant cells expressing RANK. In patients with giant cell tumour of bone, denosumab binds to RANKL, significantly reducing or eliminating osteoclast-like giant cells. Consequently, osteolysis is reduced and proliferative tumour stroma can be replaced with non-proliferative, differentiated, woven new bone which may show an increase in density.

Hypercalcaemia of malignancy refractory to intravenous bisphosphonates

The primary aetiology of both skeletal and humoral hypercalcaemia of malignancy is increased bone resorption, which leads to elevated calcium concentrations in the extracellular fluid. The increase in bone resorption is initiated by the release of signalling molecules such as PTHrP, prostaglandins, and cytokine by malignant and stromal cells. These molecules stimulate osteoblasts and other stromal cells to express RANKL, which upon binding its receptor RANK upregulates osteoclast recruitment and differentiation and thus bone resorption, with a resultant increase in calcium concentrations of the extracellular fluid and serum. Denosumab binds to RANKL preventing RANK/RANKL mediated osteoclast formation, function, and survival thereby lowering serum calcium levels.

Pharmacodynamics

In a phase 2 study of IV-bisphosphonate naïve patients with breast cancer and bone metastases, subcutaneous (SC) doses of denosumab 120 mg every 4 weeks (Q4W), caused a rapid reduction in the markers of bone resorption: urinary N-telopeptide corrected for creatinine (uNTx/Cr) and serum C-telopeptide (sCTx) with median reduction of 82% for uNTx/Cr within 1 week. Reductions in bone resorption markers were maintained, with median uNTx/Cr reductions of 74% to 82% from weeks 2 to 25 of continued 120 mg Q4W dosing. Median reduction of approximately 80% in uNTx/Cr from baseline after 3 months of treatment were also observed across 2075 denosumab-treated advanced cancer patients (breast, prostate, multiple myeloma or other solid tumours) naïve to IV-bisphosphonate in the phase 3 clinical trials.

Similarly, in a phase 2 study of patients with advanced malignancies and bone metastases (including subjects with multiple myeloma and bone disease) who were receiving intravenous bisphosphonate therapy, yet had uNTx/Cr levels > 50 nM/mM, SC dosing of denosumab administered either every 4 weeks or every 12 weeks caused an approximate 80% reduction in uNTx/Cr from baseline after 3 and 6 months of treatment. Overall, 97% of patients in the denosumab groups had at least one uNTx/Cr value < 50 nM/mM up to week 25 of the study.

In a phase 3 study of patients with newly diagnosed multiple myeloma who received SC doses of denosumab 120 mg every 4 weeks (Q4W), median reductions in uNTx/Cr of approximately 75% were observed by week 5. Reductions in bone turnover markers were maintained, with median reductions of 74% to 79% for uNTx/Cr from weeks 9 to 49 of continued 120 mg Q4W dosing.

In a phase 2 study of patients with giant cell tumour of bone who received subcutaneous doses of denosumab 120 mg every 4 weeks (Q4W) with loading doses on days 8 and 15 of the initial 4-week treatment period, median reductions in uNTx/Cr and sCTx of approximately 80% were observed by week 9. Reductions in bone turnover markers were maintained, with median reductions of 56% to 77% for uNTx/Cr and 79% to 83% for sCTx from weeks 5 to 25 of continued 120 mg Q4W dosing.

Comparative non-clinical pharmacology and toxicology

Pharmacodynamic comparability between WYOST and the reference medicine (Xgeva) was demonstrated in *in vitro* studies.

Comparability of WYOST with reference medicine (Xgeva)

The pharmacodynamic equivalence of WYOST and the reference medicine, in terms of inhibition of the serum bone turnover marker CTX (as percent change from baseline), was demonstrated via the area under the effect curve up to 39 weeks following administration in

healthy male volunteers and up to 26 weeks in postmenopausal women with osteoporosis.


Clinical trials

Clinical efficacy in patients with bone metastases from solid tumours

Efficacy and safety of 120 mg denosumab subcutaneously every 4 weeks or 4 mg zoledronic acid (dose-adjusted for reduced renal function) IV every 4 weeks were compared in three randomised, double blind, active controlled studies, in IV-bisphosphonate naïve patients with advanced malignancies involving bone. A total of 2,046 adults with breast cancer with at least one bone metastasis (Study 20050136), 1,776 adults with other solid tumours (including non-small cell lung cancer, renal cell cancer, colorectal cancer, small cell lung cancer, bladder cancer, head and neck cancer, gastrointestinal/genitourinary cancer and others, excluding breast and prostate cancer) with at least one bone metastasis or multiple myeloma (Study 20050244), and 1,901 men with castrate-resistant prostate cancer with at least one bone metastasis (Study 20050103) were included. The primary and secondary endpoints evaluated the occurrence of one or more skeletal related events (SREs) defined as any of the following: pathologic fracture, radiation therapy to bone, surgery to bone or spinal cord compression.

Denosumab reduced the risk of developing a SRE, or developing multiple SREs (first and subsequent) in patients with advanced malignancies involving bone (see Figure 1 and Table 2).

Figure 1. Kaplan-Meier Plot of Time to First On-Study SRE



N = number of subjects randomised

Table 2. Efficacy Results in Patients with Advanced Malignancies Involving Bone

	Study 20050136 breast cancer		Study 20050244 other solid tumours or multiple myeloma		Study 20050103 prostate cancer		Combined advanced cancer	
	Denosumab	zoledronic acid	Denosumab	zoledronic acid	Denosumab	zoledronic acid	Denosumab	zoledronic acid
N	1026	1020	886	890	950	951	2862	2861
First SRE								
Median time (months)	NR	26.4	20.6	16.3	20.7	17.1	27.6	19.4
Diff in median time (months)	NA		4.2		3.5		8.2	
Hazard ratio (95% CI)	0.82 (0.71, 0.95)		0.84 (0.71, 0.98)		0.82 (0.71, 0.95)		0.83 (0.76, 0.90)	
Risk reduction (%)	18		16		18		17	
Non-inferiority p-value	< 0.0001†		0.0007†		0.0002†		< 0.0001	
Superiority p-value	0.0101†		0.0619†		0.0085†		< 0.0001	
Proportion of subjects (%)	30.7	36.5	31.4	36.3	35.9	40.6	32.6	37.8
First and Subsequent SRE*								
Mean number/patient	0.46	0.60	0.44	0.49	0.52	0.61	0.48	0.57
Rate ratio (95% CI)	0.77 (0.66, 0.89)		0.90 (0.77, 1.04)		0.82 (0.71, 0.94)		0.82 (0.75, 0.89)	
Risk reduction (%)	23		10		18		18	

Superiority p-value	0.0012†		0.1447†		0.0085†		< 0.0001	
SMR per year	0.45	0.58	0.86	1.04	0.79	0.83	0.69	0.81
First Radiation to Bone								
Median time (months)	NR	NR	NR	NR	NR	28.6	NR	33.2
Hazard ratio (95% CI)	0.74 (0.59, 0.94)		0.78 (0.63, 0.97)		0.78 (0.66, 0.94)		0.77 (0.69, 0.87)	
Risk reduction (%)	26		22		22		23	
Superiority p-value	0.0121		0.0256		0.0071		< 0.0001	

NR = not reached; NA = not available; CI = confidence interval; SRE = skeletal related event; SMR = skeletal morbidity rate: defined as the ratio of the number of occurrence of any SRE for a subject, allowing 1 event per assessing period (e.g., 3 weeks), divided by the subject's time at risk; †Adjusted p-values are presented for studies 1, 2 and 3 (first SRE and first and subsequent SRE endpoints); *Accounts for all skeletal events over time; only events occurring \geq 21 days after the previous event are counted.

In a post-hoc analysis of Study 20050244 (including solid tumours, excluding multiple myeloma), denosumab reduced the risk of developing a SRE by 19% ($p = 0.0168$) and developing multiple SREs by 15% ($p = 0.0479$) compared with zoledronic acid with the median time to first SRE delayed by 6 months.

Disease progression and overall survival in advanced malignancies involving bone

Disease progression was similar between denosumab and zoledronic acid in all three studies and in the pre-specified analysis of all three-studies combined.

In all three studies overall survival was balanced between denosumab and zoledronic acid in patients with advanced malignancies involving bone: patients with breast cancer (hazard ratio [95% CI] was 0.95 [0.81, 1.11]), patients with prostate cancer (hazard ratio [95% CI] was 1.03 [0.91, 1.17]), and patients with other solid tumours or multiple myeloma (hazard ratio [95% CI] was 0.95 [0.83, 1.08]). A post-hoc analysis in Study 20050244 (patients with other solid tumours or multiple myeloma) examined overall survival for the three tumour types used for stratification (non-small cell lung cancer, multiple myeloma, and other).

Overall survival was longer for denosumab in non-small cell lung cancer (hazard ratio [95% CI] of 0.79 [0.65, 0.95]; $n = 702$) and longer for zoledronic acid in multiple myeloma (hazard ratio [95% CI] of 2.26 [1.13, 4.50]; $n = 180$) and similar between the denosumab and zoledronic acid groups in other tumour types (hazard ratio [95% CI] of 1.08 [0.90, 1.30]; $n=894$). This study did not control for prognostic factors and anti-neoplastic treatments. In a combined pre-specified analysis from all three studies, overall survival was similar between denosumab and zoledronic acid (hazard ratio [95% CI] of 0.99 [0.91, 1.07]).

Clinical efficacy in patients with multiple myeloma

Denosumab was evaluated in an international, randomised (1:1), double-blind, active-controlled study comparing denosumab with zoledronic acid in patients with newly diagnosed yymmdd-WYOST-pi-v0.3

multiple myeloma (Study 20090482).

In this study, 1718 multiple myeloma patients with at least 1 bone lesion were randomised to receive 120 mg denosumab subcutaneously every 4 weeks or 4 mg zoledronic acid intravenously (IV) every 4 weeks (dose adjusted for renal impairment and patients with creatinine clearance less than 30 mL/min were excluded based on ZOMETA[®] prescribing information). The primary outcome measure was demonstration of non-inferiority of time to first skeletal-related event (SRE) as compared to zoledronic acid. Secondary outcome measures included superiority of time to first SRE, superiority of time to first and subsequent SRE, and overall survival. An SRE was defined as any of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.

In this study, randomisation was stratified by intent to undergo autologous peripheral blood stem cell (PBSC) transplantation (yes or no), the anti-myeloma agent being utilised/planned to be utilised in first-line therapy [novel therapy-based or non-novel therapy-based (novel therapies include bortezomib, lenalidomide, or thalidomide)], stage at diagnosis (International Staging System I or II or III), previous SRE (yes or no), and region (Japan or other countries). Across both study arms, 54.5% of patients intended to undergo autologous PBSC transplantation, 95.8% of patients utilised/planned to utilise a novel anti-myeloma agent in first-line therapy, and 60.7% of patients had a previous SRE. The number of patients across both study arms with ISS stage I, stage II, and stage III at diagnosis were 32.4%, 38.2%, and 29.3%, respectively.

Median age was 63 years, 82.1% of patients were White, and 45.6% of patients were women. The median number of doses administered was 16 for denosumab and 15 for zoledronic acid. In patients with newly diagnosed multiple myeloma, denosumab was non-inferior to zoledronic acid in delaying the time to first SRE following randomisation (see Figure 2 and Table 3).

Figure 2. Kaplan-Meier Plot for Time to First On-Study SRE




Table 3. Efficacy Results for Denosumab Compared to Zoledronic Acid in Patients with Newly Diagnosed Multiple Myeloma

	Denosumab (N = 859)	Zoledronic Acid (N = 859)
First SRE		
Number of Patients who had SREs (%)	376 (43.8)	383 (44.6)
Median Time to SRE (months)	22.8 (14.7, NE)	23.98 (16.56, 33.31)
Hazard ratio (95% CI)	0.98 (0.85, 1.14)	
Non-inferiority p-value	0.010	
Superiority p-value*	0.84	
Components of First SRE		
Radiation to Bone	47 (5.5)	62 (7.2)
Pathological Fracture	342 (39.8)	338 (39.3)
Surgery to Bone	37 (4.3)	48 (5.6)
Spinal Cord Compression	6 (0.7)	4 (0.5)
First and Subsequent SRE		
Mean number of events/patient	0.66	0.66
Rate Ratio (95% CI)	1.01 (0.89, 1.15)	
Superiority p-value*	0.84	
Skeletal Morbidity Rate per year	0.61	0.62

NE = not estimable


SRE = skeletal-related events CI = confidence interval

*Adjusted p-value presented

Overall survival and progression free survival in multiple myeloma


The hazard ratio between denosumab and zoledronic acid treatment groups and 95% CI for overall survival (OS) was 0.90 (0.70, 1.16) (see Figure 3). Progression-free survival (PFS) was assessed as an exploratory endpoint. Median PFS (95% CI) was 46.1 (34.3, not estimable) months for the denosumab treatment group and 35.4 (30.2, not estimable) months for the zoledronic acid group (HR [95% CI] of 0.82 [0.68, 0.99]) (see Figure 4).

Figure 3. Kaplan-Meier Plot of Overall Survival



N = number of subjects randomized

Figure 4. Kaplan-Meier Plot of Progression-free Survival



N = number of subjects randomized

Effect on pain

Levels of pain were examined using the Brief Pain Inventory – Short Form (BPI-SF) questionnaire as an exploratory endpoint.

For pain measures based on BPI-SF, the point estimate (95% CI) of the average AUC of the

pain severity score, relative to baseline, was -0.72 (-0.92, -0.51) for denosumab and -0.40 (-0.59, -0.20) for zoledronic acid, with a point estimate (95% CI) for the treatment difference of -0.32 (-0.60, -0.04) and $p = 0.024$.

Denosumab and zoledronic acid showed similar results in time to, and proportion by visit for ≥ 2 - point decrease, ≥ 2 -point increase, and > 4 -point in worst pain score.

Other measures showed similar results between denosumab and zoledronic acid, and results suggested that there were unlikely to be clinically significant differences between denosumab and zoledronic acid with regards to effects on pain.

Clinical efficacy in adults and skeletally mature adolescents with giant cell tumour of bone

The safety and efficacy of denosumab was studied in two phase 2 open-label, single arm trials (Studies 20040215 and 20062004). The interim analysis, enrolled 305 patients with giant cell tumour of bone that was either unresectable or for which surgery would be associated with severe morbidity. Patients received 120 mg denosumab subcutaneously every 4 weeks with a loading dose of 120 mg on days 8 and 15 of the initial 4-week treatment period.

Study 20040215 enrolled 37 adult patients with histologically confirmed unresectable or recurrent giant cell tumour of bone. The main outcome measure of the trial was response rate, defined as either at least 90% elimination of giant cells relative to baseline (or complete elimination of giant cells in cases where giant cells represent $< 5\%$ of tumour cells), or a lack of progression of the target lesion by radiographic measurements in cases where histopathology was not available.

Of the 35 patients included in the efficacy analysis, 85.7% (95% CI: 69.7, 95.2) had a treatment response to denosumab. All 20 patients (100%) with histology assessments met response criteria. Of the remaining 15 patients, 10 (67%) met response criteria based on radiology data.

Study 20062004 interim analysis enrolled 282 adult or skeletally mature adolescents with giant cell tumour of bone. Patients were assigned to one of three cohorts: Cohort 1 included patients with surgically unsalvageable disease (e.g., sacral, spinal, or multiple lesions, including pulmonary metastases); Cohort 2 included patients with surgically salvageable disease whose planned surgery was associated with severe morbidity (e.g., joint resection, limb amputation, or hemipelvectomy); Cohort 3 included patients previously participating in 20040215 and rolled over into this study. The secondary outcome measures of the study were time to disease progression (based on investigator assessment) for Cohort 1 and proportion of patients without any surgery at month 6 for Cohort 2. Pain outcomes and investigator determined clinical benefit were also assessed.

In Cohort 1, median time to disease progression was not reached, as only 6 of the 169 treated patients (3.6%) had disease progression. In Cohort 2, denosumab prolonged the time to surgery, reduced the morbidity of planned surgery, and reduced the proportion of patients undergoing surgery (see Table 4). Sixty-four of the 71 (90.1%; 95% CI: 80.7%, 95.9%) evaluable patients treated with denosumab had not undergone surgery by month 6. Overall, of 100 patients for whom surgery was planned, 74 patients (74%) had no surgery performed, and 16 patients (16%) underwent a less morbid surgical procedure from that planned at baseline (see Table 4).

A retrospective independent review of radiographic imaging data was performed for patients enrolled in 20040215 and 20062004. Of the 305 patients enrolled in these studies, 190 had at least 1 evaluable timepoint response and were included in the analysis (see Table 5).

Patients were evaluated by the following response criteria to determine objective tumour response:

- Modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1) to evaluate tumour burden based on computed tomography (CT)/magnetic resonance imaging (MRI)
- Modified European Organisation for Research and Treatment of Cancer (EORTC) criteria to evaluate metabolic response using fluorodeoxyglucose positron emission tomography (FDG-PET)
- Modified Inverse Choi criteria to evaluate tumour size and density using Hounsfield units based on CT/MRI (Density/Size)

Denosumab achieved objective tumour responses in 136 of these 190 patients (71.6%; 95% CI: 64.6, 77.9) (see Table 5). The median time to response was 3.1 months (95% CI: 2.89, 3.65). The median duration of response was not estimable, as few patients experienced disease progression, with a median follow-up of 13.4 months. Efficacy results in skeletally mature adolescents appeared to be similar to those observed in adults.

Table 4. Distribution of Planned Versus Actual Surgery in Patients with Giant Cell Tumour of Bone (Cohort 2)

Surgical Procedure, n	Baseline Planned (N = 100)	Actual Total (N = 26)
Total number of surgeries	100	26
Major surgeries	44	3
Hemipelvectomy	4	0
Amputation	17	0
Joint/prosthesis replacement	9	1
Joint resection	14	2
Marginal excision, en bloc excision, or en bloc resection	42	6
Curettage	13	16
Other	1	1
No surgery	0	74

Table 5. Objective Treatment Response in 305 Patients with Giant Cell Tumour of Bone

	Number of patients evaluable for the endpoint	Number of patients with the endpoint	Proportion (%) (95% CI) ^a	KM estimate of median (95% CI) (Months)
Proportion of patients with an objective tumour response (CR, PR)				
Based on best response	190	136	71.6(64.6, 77.9)	-
RECIST 1.1	187	47	25.1(19.1, 32.0)	-
EORTC	26	25	96.2(80.4, 99.9)	-
Density/Size	176	134	76.1(69.1, 82.2)	-
Duration of objective tumour response (time to PD from the first objective tumour response)				
Based on best response	136	1	0.7	NE (NE, NE) ^b
RECIST 1.1	47	3	6.4	NE (19.94, NE)
EORTC	25	0	0.0	NE (NE, NE)
Density/Size	134	1	0.7	NE (NE, NE)
Time to first objective tumour response				
Based on best response	190	136	71.6	3.1 (2.89, 3.65)
RECIST 1.1	187	47	25.1	NE (20.93, NE)
EORTC	26	25	96.2	2.7 (1.64, 2.79)
Density/Size	176	134	76.1	3.0 (2.79, 3.48)

^a Exact Confidence Interval

^b NE = Not Estimable

Effect on pain

In Study 20062004 interim analysis, Cohorts 1 and 2 combined, a clinically meaningful reduction in worst pain (i.e., ≥ 2 -point decrease from baseline) was reported for 31.4% of patients at risk (i.e. those who had a worst pain score of ≥ 2 at baseline) within 1 week of treatment, and $\geq 50\%$ at week 5. These pain improvements were maintained at all subsequent evaluations. In a post-hoc analysis, at least half of evaluable patients had a $\geq 30\%$ reduction in worst pain score from baseline at all post-baseline time points beginning at week 9. Overall, pain improvement and clinical benefit did not correlate with objective tumour response.

Clinical efficacy in treatment of hypercalcaemia of malignancy

The safety and efficacy of denosumab was studied in a phase 2 open-label, single-arm trial (Study 20070315) that enrolled 33 patients with hypercalcaemia of malignancy (with or without bone metastases) refractory to treatment with intravenous bisphosphonate. In this study, refractory hypercalcaemia of malignancy was defined as an albumin-corrected serum calcium (CSC) of >12.5 mg/dL (3.1 mmol/L) despite treatment with intravenous bisphosphonate in the last 7-30 days.


Twenty-six (79%) patients had advanced solid tumours and 7 (21%) patients had advanced hematologic malignancies. Twenty-five patients (76%) had poor performance status (Eastern Cooperative Oncology Group [ECOG] ≥ 2) at baseline. Metastatic disease was present in 30 (91%) patients and metastatic bone disease in 13 (39%) patients at baseline. Three (9%) patients had non-metastatic disease, 2 with myeloma and 1 with non-Hodgkin’s lymphoma. Nineteen patients (58%) reported symptoms related to hypercalcaemia of malignancy at baseline. At the time of enrollment, the median serum calcium level was 13.7 mg/dL (3.42 mmol/L).

The primary endpoint was the proportion of patients achieving a response, defined as CSC ≤ 11.5 mg/dL (2.9 mmol/L), within 10 days after denosumab administration. The secondary objectives were to determine the duration of the treatment effect, the time to response, the time to relapse/nonresponse and to evaluate changes in CSC level from baseline.

Patients received denosumab subcutaneously every 4 weeks with additional 120 mg doses on days 8 and 15 of the first month of therapy.

Denosumab was associated with rapid and sustained decreases in serum calcium in the majority of patients including those with or without bone metastases (see Figure 5 and Table 6).

Figure 5. Corrected Serum Calcium by Visit (median and interquartile range)



N = Number of subjects who received at least 1 dose of denosumab
 n = Number of subjects who had no missing data at baseline and the timepoint of interest
 BL = Baseline

Table 6. Efficacy Results in Patients with Skeletal or Humoral Hypercalcaemia of Malignancy Refractory to Treatment with Intravenous Bisphosphonate

	Number of patients evaluable for the endpoint	Number of patients with the endpoint	Proportion of patients (%) (95% CI)	KM ^g estimate (median) (95% CI)
Response by Day 10^a	33	21	63.6 (45.1, 79.6)	--
Overall on- study response	33	23	69.7 (51.3, 84.4)	--
Duration of response^b	23	10 ^c	--	104 (9.0, NE ^h)
Complete response by Day 10^c	33	12	36.4 (20.4, 54.9)	--
Overall on- study complete response	33	21	63.6 (45.1, 79.6)	--
Duration of complete response^d	21	14 ^f	--	34 (1.0, 134.0)

^a CSC ≤ 11.5 mg/dL (2.9 mmol/L)

^b Number of days from the occurrence of first response until last CSC ≤ 11.5 mg/dL (2.9 mmol/L)

^c CSC ≤ 10.8 mg/dL (2.7 mmol/L)

^d Number of days from the occurrence of first complete response until last CSC ≤ 10.8 mg/dL (2.70 mmol/L)

^e Number of subjects whose CSC level reached > 11.5 mg/dL after the first response

^f Number of subjects whose CSC level reached > 10.8 mg/dL after the first complete response

^g Kaplan-Meier

^h Not estimable

Symptom improvement in patients with refractory hypercalcaemia of malignancy

In Study 20070315, data regarding hypercalcaemia of malignancy symptoms were collected on a dedicated case report form. In the study population, a total of 48 hypercalcaemia of malignancy symptoms were reported in 19 patients at baseline. Each symptom status was based on the best status by study day 10.

- 8 (42%) patients reported resolution of at least 1 symptom
- 4 (21%) patients reported resolution of all symptoms
- 15 (31%) of the symptoms present at baseline resolved
- 5 (10%) of the symptoms improved
- 2 (4%) of the symptoms got worse
- 26 (54%) of the symptoms remained stable

Nine patients reported a total of 12 hypercalcaemia of malignancy symptoms of cognitive impairment at baseline. Each symptom status was based on the best status by study day 10.

- 5 (56%) of patients reported resolution of at least 1 symptom of cognitive impairment

- 4 (44%) of patients reported resolution of all symptoms of cognitive impairment
- 7 (58%) of the symptoms of cognitive impairment present at baseline resolved
- 1 (8%) cognitive impairment symptom worsened
- 4 (33%) of the cognitive impairment symptoms remained stable

Comparability of WYOST with reference medicine (Xgeva)

Information in this section is based on studies which include other denosumab containing product (JUBBONTI). Results of this study are relevant to establish biosimilarity between WYOST and the reference medicine as it is the most relevant clinical setting for comparative assessment. The mechanism of action is identical between all denosumab indications.

Results of study CGP24112301 in postmenopausal women with osteoporosis

Study CGP24112301 demonstrated similar clinical efficacy of JUBBONTI and Prolia® in women with postmenopausal osteoporosis (PMO) in terms of the percentage change from baseline (%CfB) of lumbar spine bone mineral density (LS-BMD) at Week 52. Improvement in LS-BMD was similar in both treatment groups. The results are shown in Table 7 below.

Table 7. Percentage Change From Baseline in LS-BMD at Week 52

Comparison	Adjusted mean % CfB in LS-BMD (SE)		Comparison of adjusted means: JUBBONTI vs Prolia	
	JUBBONTI (N=255)	Prolia (N=257)	Difference (JUBBONTI – Prolia)	95% CI
JUBBONTI vs Prolia	4.963 (0.2630)	5.140 (0.2627)	-0.177	(-0.830,0.475)

% CfB: Change from baseline; SE: Standard error

A mixed-model repeated measures analysis was performed for %CfB in LS-BMD including the following variables: treatment (JUBBONTI, Prolia), prior bisphosphonate use (yes, no), dual energy X-ray absorptiometry machine type (Lunar, Hologic), visit (Week 26, Week 52), interaction between visit and treatment, and baseline LS-BMD value as a continuous covariate. Missing data is assumed to be missing at random. The equivalence margins are set to [-1.45, 1.45].

5.2. PHARMACOKINETIC PROPERTIES

Absorption

Following subcutaneous administration, bioavailability was 62%.

Distribution

Denosumab displayed non-linear pharmacokinetics with dose over a wide dose range, but approximately dose-proportional increases in exposure for doses of 60 mg (or 1 mg/kg) and higher.

In subjects with advanced cancer who received multiple doses of 120 mg every 4 weeks (Q4W) an approximate 2-fold accumulation in serum denosumab concentrations was observed and steady-state was achieved by 6 months, consistent with time-independent pharmacokinetics.

At steady-state, the mean serum trough concentration was 20.6 µg/mL (range: 0.456 to 56.9 µg/mL). In subjects with multiple myeloma who received 120 mg every 4 weeks, median trough levels varied by less than 8% between months 6 and 12.

In subjects with giant cell tumour of bone who received 120 mg every 4 weeks with a loading dose on days 8 and 15, steady-state levels were achieved within the first month of treatment. Between weeks 9 and 49, median trough levels varied by less than 9%.

Metabolism

Denosumab is composed solely of amino acids and carbohydrates as native immunoglobulin and is unlikely to be eliminated via hepatic metabolic mechanisms. Its metabolism and elimination are expected to follow the immunoglobulin clearance pathways, resulting in degradation to small peptides and individual amino acids.

Excretion

In subjects with advanced cancer who discontinued doses of 120 mg every 4 weeks, the mean half-life was 28 days (range: 14 to 55 days).

Special populations

A population pharmacokinetic analysis showed no notable difference in pharmacokinetics with age (18 to 87 years), race, body weight (36 to 174 kg), or across patients with solid tumours, multiple myeloma, and giant cell tumour of bone. The pharmacokinetics and pharmacodynamics of denosumab were similar in patients transitioning from IV bisphosphonate therapy.

Elderly

The pharmacokinetics of denosumab was not affected by age (18 to 87 years).

Paediatric

The pharmacokinetic profile has not been assessed in those ≤ 18 years.

Impaired hepatic function

The pharmacokinetic profile has not been assessed in patients with impaired hepatic function.

Impaired renal function

In studies of denosumab (60 mg, N = 55 and 120 mg, N = 32) in patients without advanced malignancies but with varying degrees of renal function, including patients on dialysis, the degree of renal impairment had no effect on the pharmacokinetics and pharmacodynamics of denosumab. Dose adjustment for renal impairment is not necessary.

Comparability of WYOST with reference medicine (Xgeva)

Information in this section is based on studies which include other denosumab containing product (JUBBONTI). Results of both studies confirmed biosimilarity between WYOST and the reference medicine.

A comparable pharmacokinetic (PK) profile of WYOST and the reference medicine (Xgeva) was also demonstrated in a randomised, double-blind, single-dose, three-arm parallel study in healthy male volunteers (Study CGP24112101). In this study, similarity with respect to the PK

parameters AUC_{inf} , AUC_{last} , and C_{max} was shown between WYOST and the reference medicine. A subtherapeutic dose of 35 mg was used to demonstrate comparable PK profiles in healthy volunteers. A 35 mg covers both elimination pathways, target mediated drug disposition (TMDD) i.e. non-linear and saturable target binding to RANKL and linear IgG clearance (binding to FcRn) and ensured a higher sensitivity to detect potential PK and PD differences between WYOST and the reference medicine (Xgeva) than the approved reference medicine (Xgeva) dose of 120 mg.

A comparable PK profile of JUBBONTI and the reference medicine (Prolia) was demonstrated in a randomised, double-blind trial in postmenopausal women with osteoporosis (Study CGP24112301). In this study, similarity with respect to the PK parameters AUC_{inf} and C_{max} after the first dose was shown between JUBBONTI and the reference medicine.

Statistical summaries of the primary PK parameters of study CGP24112101 and study CGP24112301 are provided below.

Table 8. Summary Statistical Analysis of the Primary Pharmacokinetic Parameters in Study GP24112101

Test vs Reference (Comparison)	Parameter (unit)	Adjusted Geo-Mean				Geo-Mean Ratio Test/Reference	
		Test	n	Reference	n	Point Estimate	(90% CI)
WYOST vs Xgeva ¹	AUC_{inf} (day*ng/mL)	129000	162	118000	167	1.09	(1.03, 1.16)
	AUC_{last} (day*ng/mL)	126000	165	117000	167	1.08	(1.01, 1.14)
	C_{max} (ng/mL)	2920	165	2850	167	1.02	(0.97, 1.08)
WYOST vs Xgeva ²	AUC_{inf} (day*ng/mL)	129000	162	121000	161	1.06	(1.00, 1.13)
	AUC_{last} (day*ng/mL)	126000	165	120000	161	1.05	(0.99, 1.11)
	C_{max} (ng/mL)	2920	165	2900	161	1.00	(0.95, 1.06)
Xgeva ¹ vs Xgeva ²	AUC_{inf} (day*ng/mL)	118000	167	121000	161	0.97	(0.92, 1.03)
	AUC_{last} (day*ng/mL)	117000	167	120000	161	0.98	(0.92, 1.04)
	C_{max} (ng/mL)	2850	167	2900	161	0.98	(0.93, 1.04)

Xgeva¹ = EU-Xgeva; Xgeva² = US-Xgeva;

AUC_{inf} =area under the concentration-time curve extrapolated to infinity; AUC_{last} =area under the concentration-time curve measured until the last measurable concentration; CI=confidence interval; C_{max} =maximum concentration; n=number of subjects included in the analysis.

An analysis of covariance was performed on log-transformed AUC_{inf} , AUC_{last} and C_{max} including treatment as a factor and weight as a covariate. The similarity margins are set to 0.80 and 1.25.

Table 9. Summary Statistical Analysis of the Primary Pharmacokinetic Parameters in Study GP24112301

Test vs Reference (Comparison)	Parameter (unit)	Adjusted Geo-Mean		Geo-Mean Ratio		
		Test	n	Reference	n	Point Estimate (90% CI)
JUBBONTI vs Prolia	AUC _{inf} (day*ng/mL)	366000	247	369000	246	0.99 (0.93, 1.05)
	C _{max} (ng/mL)	6910	260	7120	258	0.97 (0.92, 1.03)

AUC_{inf}=area under the concentration-time curve extrapolated to infinity; CI=confidence interval; C_{max}=maximum concentration; n=number of subjects included in the analysis.
 An analysis of covariance was performed on log-transformed AUC_{inf} and C_{max} including treatment as a factor and weight as a covariate. The similarity margins are set to 0.80 and 1.25.

Immunogenicity

Denosumab pharmacokinetics and pharmacodynamics were not affected by the formation of binding antibodies to denosumab and were similar in men and women.

In clinical studies, no neutralising antibodies for denosumab have been observed in advanced cancer patients or giant cell tumour of the bone patients. Using a sensitive immunoassay, < 1% of patients treated with denosumab for up to 3 years tested positive for non-neutralising binding antibodies with no evidence of altered pharmacokinetics, toxicity, or clinical response.

Immunogenicity of WYOST

Information in this section is based on studies which include other denosumab containing product (JUBBONTI).

In clinical studies comparing JUBBONTI and Prolia, immunogenicity was assessed for 527 patients treated for 52 weeks and was observed to be similar in both treatment groups. Neutralising antibodies (NAb) were rare (~1%) and the vast majority of the non neutralising binding antibodies (ADA) was transient and only <1% had a measurable titer. There was no evidence that immunogenicity was associated with altered pharmacokinetics, pharmacodynamics or clinical response. The results were obtained using highly sensitive assays demonstrating comparable immunogenicity profiles between JUBBONTI and Prolia.

Results of this study are relevant to establish biosimilarity between WYOST and the reference medicine (Xgeva) as it is the most relevant clinical setting for comparative assessment. The mechanism of action is identical across all denosumab indications. Pharmacokinetics and pharmacodynamics were not affected by the formation of antibodies.

5.3. PRECLINICAL SAFETY DATA

Genotoxicity

The genotoxic potential of denosumab has not been evaluated. Denosumab is a recombinant protein comprised entirely of naturally occurring amino acids and contains no inorganic or synthetic organic linkers or other non-protein portions. Therefore, it is unlikely that denosumab or any of its derived fragments would react with DNA or other chromosomal material.

Carcinogenicity

The carcinogenic potential of denosumab has not been evaluated in long-term animal studies. In view of the mechanism of action of denosumab, it is unlikely that the molecule would be capable of inducing tumour development or proliferation.

6. PHARMACEUTICAL PARTICULARS

6.1. LIST OF EXCIPIENTS

Each single-use vial of WYOST contains 78.9 mg sorbitol, 1.85 mg glacial acetic acid, 0.17 mg polysorbate 20, hydrochloric acid, sodium hydroxide and water for injections.

6.2. INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3. SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4. SPECIAL PRECAUTIONS FOR STORAGE

It is recommended to store vials in a refrigerator at 2°C to 8°C in the original carton. Do not freeze. Protect from direct light. Do not shake the vial. Do not expose to temperatures above 25°C.

If removed from the refrigerator, WYOST should be kept at room temperature (up to 25°C) in the original container and must be used within 30 days.

6.5. NATURE AND CONTENTS OF CONTAINER

WYOST is supplied in a single use vial (type I glass) with stopper (fluoropolymer coated elastomeric) and seal (aluminium) with flip-off cap.


Pack size: one vial.

6.6. SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7. PHYSICOCHEMICAL PROPERTIES

Chemical structure



CAS number

615258-40-7

7. MEDICINE SCHEDULE (POISONS STANDARD)

Schedule 4 – Prescription Only Medicine

8. SPONSOR

Sandoz Pty Ltd
100 Pacific Highway
North Sydney, NSW 2060
Australia
Tel 1800 726 369

9. DATE OF FIRST APPROVAL

DD/MM/YYYY

10. DATE OF REVISION

N/A

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
N/A	New registration

® Registered Trade Mark. The trade marks mentioned in this material are the property of their respective owners.